333 related articles for article (PubMed ID: 30180743)
1. Immunotherapy and radiotherapy for metastatic cancers.
Bang A; Schoenfeld JD
Ann Palliat Med; 2019 Jul; 8(3):312-325. PubMed ID: 30180743
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein MB; Krishnan S; Hodge JW; Chang JY
Nat Rev Clin Oncol; 2016 Aug; 13(8):516-24. PubMed ID: 26951040
[TBL] [Abstract][Full Text] [Related]
4. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Reverdy T; Gau M; Karabajakian A; Neidhardt EM; Fayette J
Bull Cancer; 2018 Dec; 105 Suppl 1():S35-S42. PubMed ID: 30595197
[TBL] [Abstract][Full Text] [Related]
6. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Warner AB; Postow MA
Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
[TBL] [Abstract][Full Text] [Related]
7. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Chang X; Lu X; Guo J; Teng GJ
Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
[TBL] [Abstract][Full Text] [Related]
8. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
Wirsdörfer F; de Leve S; Jendrossek V
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
10. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Nadeau BA; Fecher LA; Owens SR; Razumilava N
Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
12. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
13. Toxicities of checkpoint inhibitors: causes and management.
Postow MA
Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813
[No Abstract] [Full Text] [Related]
14. Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
Bermudez MV; Papa S
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii1-vii6. PubMed ID: 31816083
[TBL] [Abstract][Full Text] [Related]
15. Toxicities associated with checkpoint inhibitors-an overview.
Spiers L; Coupe N; Payne M
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
[TBL] [Abstract][Full Text] [Related]
16. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
[TBL] [Abstract][Full Text] [Related]
17. State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours-a German radiation oncology survey.
Käsmann L; Eze C; Dantes M; Roengvoraphoj O; Niyazi M; Belka C; Manapov F
Eur J Cancer; 2019 Feb; 108():50-54. PubMed ID: 30648629
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
19. [Synergy between radiotherapy and immunotherapy in the treatment of advanced malignancies: recent evidences of a new challenge in oncology].
Corvò R; Belgioia L
Recenti Prog Med; 2015 Jul; 106(7):322-30. PubMed ID: 26228723
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review.
Trapani S; Manicone M; Sikokis A; D'Abbiero N; Salaroli F; Ceccon G; Buti S
Crit Rev Oncol Hematol; 2019 Oct; 142():9-15. PubMed ID: 31325712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
